Skip to main content
. Author manuscript; available in PMC: 2021 Dec 9.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 Jun 27;108(4):979–986. doi: 10.1016/j.ijrobp.2020.06.020

Table 2.

Survival results

BEV, % (95% CI) BEV/pRDR, % (95% CI) P value Hazard ratio
6-mo OS 69 (54–81) 97 (80–100) .0030 10.83
12-mo OS 34 (20–48) 73 (53–86) .0008 3.48
18-mo OS 24 (12–38) 42 (24–59) .0013 2.18
24-mo OS 11 (3–23) 19 (7–35) .0016 1.85
6-mo PFS 36 (22–50) 82 (63–92) <.0001 5.68
12-mo PFS 16 (6–29) 56 (36–72) <.0001 3.84
18-mo PFS 9 (2–21) 22 (9–39) .0002 2.58
24-mo PFS 3 (0–13) 15 (5–31) .0002 2.51

Abbreviations: CI = confidence interval; OS = overall survival; PFS = progression-free survival; pRDR = pulsed reduced dose rate radiation therapy.

Percent OS and PFS at 6, 12, 18, and 24 months were significantly better in the BEV/pRDR group compared to the BEV group.